| TMIC-58. ALTERATIONS IN GLIOBLASTOMA TUMOR MICROENVIRONMENT TRANSCRIPTOME AFTER TREATMENT WITH PEMBROLIZUMAB N Majd, L Yang, G Williford, K Alfaro-Munoz, P Dasgupta, A Heimberger, ... Neuro-Oncology 25 (Supplement_5), v291-v291, 2023 | 1 | 2023 |
| Metastatic extraneural glioblastoma diagnosed with molecular testing NK Majd, HH Vo, CA Moran, SP Weathers, IW Song, GL Williford, J Rodon, ... The Oncologist, oyae115, 2024 | | 2024 |
| Ivosidenib off-label use for IDH mutant gliomas: The MD Anderson Cancer Center real life experience. K Lam, HY Lin, G Williford, C Wathoo, N Majd Journal of Clinical Oncology 41 (16_suppl), e14022-e14022, 2023 | | 2023 |
| An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas TA Gregory, GL Williford, JM Maronge, K Alfaro, GN Fuller, J de Groot, ... Neuro-oncology 25 (4), 808-809, 2023 | | 2023 |
| Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study A Dono, K Alfaro-Munoz, Y Yan, CA Lopez-Garcia, Z Soomro, G Williford, ... Neurosurgery 90 (5), 515-522, 2022 | | 2022 |
| Primary Brain Tumor Patients Experience Significant Sleep Disturbance; An Analysis of Clinical Characteristics and Sleep Parameters (4488) Z Soomro, K Alfaro, D Balachandran, C Bornstein, M Perez, J Song, ... Neurology 96 (15 Supplement), 2021 | | 2021 |
| PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE M Jane Lim-Fat, G Youssef, M Touat, B Iorgulescu, E Woodward, ... Neuro-Oncology 22 (Supplement_2), ii164-ii164, 2020 | | 2020 |
| PATH-05. A RETROSPECTIVE STUDY OF TREATMENT STRATEGIES AND OUTCOMES IN WHO GRADE II AND III ISOCITRATE DEHYDROGENASE (IDH) WILD-TYPE ASTROCYTOMA A Aaroe, A Dono, M Youssef, K Alfaro-Munoz, SP Weathers, B O’Brien, ... Neuro-Oncology 22 (Suppl 2), ii164, 2020 | | 2020 |
